– USA, CA Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Mary K. Pendergast, J.D., LL.M. has been appointed to the Company’s Board of Directors effective as of July 3, 2013. Ms. Pendergast is currently President of Pendergast Consulting, a legal and regulatory consulting firm to pharmaceutical and biotechnology companies. Ms. Pendergast spent more than 18 years at the U.S. Food and Drug Administration (FDA) serving as Deputy Commissioner and Senior Advisor to the FDA Commissioner and as Associate Chief Counsel for Enforcement.
“We are delighted that Ms. Pendergast will be joining the Board. She brings significant experience and understanding of the legal and regulatory landscape across our industry and can provide invaluable strategic and practical guidance, insight, and perspective with respect to our operations, compliance, and strategy.”
Robert L. Burr, Chairman of the Board of Impax Laboratories, said: “We are delighted that Ms. Pendergast will be joining the Board. She brings significant experience and understanding of the legal and regulatory landscape across our industry and can provide invaluable strategic and practical guidance, insight, and perspective with respect to our operations, compliance, and strategy.”
Ms. Pendergast will be a member of the Board’s Compliance Committee, which was established to provide oversight for all activities of the Company related to the FDA warning letter for the Hayward site including obtaining approval of the Company’s New Drug Application for an investigational drug, RYTARYTM, for the treatment of idiopathic Parkinson’s disease.
Prior to founding her own firm in 2003, she was Executive Vice President, Government Affairs, at Elan Corporation from 1998 to 2003. Ms. Pendergast served as Deputy Commissioner and Senior Advisor to the Commissioner at the FDA from 1990 to 1997, and also served as Associate Chief Counsel for Enforcement at the FDA from 1979 to 1990.
Ms. Pendergast is on the Board of Directors of AesRx, G2B pharma, and the Arch Foundation. She received her LL.M., J.D., and B.A. degrees from Yale Law School, the University of Iowa College of Law, and Northwestern University, respectively.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.